Sentences with phrase «for patients with lung cancer»
April 4, 2016 Precision medicine brings new hope to those with advanced urothelial cancer Five of six patients with advanced metastatic urothelial cancer and at least one of two specific genetic abnormalities, responded to treatment with afatinib, which was approved in 2013 by the Food and Drug Administration for patients with lung cancer, researchers report online in the Journal of Clinical Oncology.
http://www.uchospitals.edu/
On October 2, 2015, the FDA approved the immunotherapy drug pembrolizumab (Keytruda ®), made by Merck, as second - line treatment for patients with lung cancer, the leading cause of cancer - related death in the U.S. and the world.
Not exact matches
That leaves Merck largely free of competitors in the near - term in its quest to become a go - to, first - line option for lung cancer patients in combination with chemotherapy (Merck recently surprised investors with an early FDA filing for that combination).
Related Articles: Merck's Keytruda held back by docs who don't want to wait for diagnostics Bristol's Opdivo - Yervoy combo ups response rates in first - line lung cancer patients Roche's Tecentriq bursts onto immuno - oncology scene, with Merck and BMS in its sights Bristol - Myers» new Opdivo ad touts biomarker advantage over Merck's Keytruda Merck's Keytruda lines up its survival data for stepped - up battle with BMS» Opdivo
They'll also jointly market Pfizer's drug Xalkori, which is approved in more than 75 countries for treating non-small cell lung cancer in patients with a certain genetic mutation.
The biotech specialist said that its updated phase 2 data in a study of its poziotinib candidate treatment for non-small cell lung cancer resulted in a preliminary confirmed objective response rate and potential progression - free survival benefit in patients with the EGFR Exon 20 Mutant form of the disease.
Patients with lung cancer are assumed to have earned it, having inhaled toxins for years.
«One of the toughest challenges of lung cancer is what to do for patients when the cancer comes back in an area that's been treated previously with radiation treatment,» said James J. Urbanic, M.D., lead author of the studies and a radiation oncologist at Wake Forest Baptist.
If hypofractionated radiation with curative intent can reduce the treatment time for lung cancer patients by half with no greater toxicity, and with equivalent — if not better — tumor control and survival outcomes, this research could result in a change in the paradigm of how a large subset of locally advanced NSCLC patients are treated.»
For example, lung cancer patients who were injected with killed M. vaccae reported better quality of life and less nausea and pain.
For the new trial, hospitals enrolled patients with advanced, squamous non-small cell lung cancer whose disease had progressed despite initial chemotherapy.
The researchers combined data from lung cancer patients in The Society of Thoracic Surgeons (STS) General Thoracic Surgery Database (GTSD) with claims data from the Centers for Medicare & Medicaid Services (CMS).
«Blocking both of these proteins could be a treatment that is beneficial for the majority of lung cancer patients,» said Dr. Habib, Associate Professor of Neurology and Neurotherapeutics with UT Southwestern's Peter O'Donnell Jr..
The drug erlotinib is prescribed to between 10 — 30 per cent of patients with non-small cell lung cancer, which accounts for 85 per cent of all lung cancer cases.
In addition, the study showed that the 5 - year survival rate for selected older patients with advanced lung cancer who were treated with surgical therapy was 29.9 % for Stage III and 26.7 % for Stage IV.
The approach is already routine for some cancer patients, such as women and men with breast cancer tumors that have high levels of a protein called HER2, or lung cancer tumors with mutations in the EGFR gene.
«Although some non-small cell lung cancer patients have increased benefit of targeted therapy or immunotherapy instead of chemotherapy, for some groups of patients with NSNSCLC, chemotherapy has been the standard treatment for more than 30 years,» Gandhi notes.
A drug approved by the Food and Drug Administration (FDA) for melanoma in combination with a common cholesterol - lowering drug may show promise in controlling cancer growth in patients with non-small cell lung cancer (NSCLC), according to new research from the Icahn School of Medicine at Mount Sinai.
«FDG PET shows tumor DNA levels in blood are linked to NSCLC aggressiveness: Insights derived from FDG PET could improve treatment selection for patients with advanced non-small cell lung cancer.»
Phase I / II clinical trial results reported at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show promising results for investigational drug brigatinib against ALK + non-small cell lung cancer (NSCLC), with 58 of 78 ALK + patients responding to treatment, including 50 of 70 patients who had progressed after previous treatment with crizotinib, the first licensed ALK inhibitor.
Combining radiation therapy with chemotherapy for patients with limited metastatic non-small cell lung cancer (NSCLC) may curb disease progression dramatically when compared to NSCLC patients who only receive chemotherapy, according to a new randomized phase II clinical trial reported today at the 59th Annual Meeting of the American Society for Radiation Oncology (ASTRO).
After a median follow - up of 11 months, 11 of the 13 patients who responded remain on the study, including one patient who had non-small cell lung cancer (NSCLC) with a ROS1 gene fusion who has had a complete response that has been maintained for more than two years.
For the study, Gabriella Hobbs, MD, and Nancy Keating, MD, MPH, of Harvard Medical School, and their colleagues surveyed 5284 patients with a new diagnosis of lung or colon cancer, and asked participants how they involved their families in decisions about their care.
They also chose to study a type of K - Ras mutant called G12C (for Glycine - 12 to Cysteine), a K - Ras mutant prevalent in about seven percent of patients with lung cancer.
Pembrolizumab is set to become a new option for first line treatment of patients with advanced lung cancer and high PD - L1 expression, according to the results of the phase III KEYNOTE - 024 trial presented at the ESMO 2016 Congress in Copenhagen and published in the New England Journal of Medicine.
«Chemotherapy may be better for certain patients with advanced lung cancer.»
In the malignant tissue, they found up to 1500 genes with mutations — a level higher than has been found for either lung cancer in smokers or skin cancer in patients with heavy exposure to ultraviolet radiation.
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the preferred treatment option for patients with advanced non-small cell lung cancer (NSCLC) who have mutations in the EGFR gene.
An international study involving Manchester researchers has found that for previously untreated lung cancer patients with a particular genetic change, a new targeted therapy is better than standard chemotherapy.
Commenting on the findings, Prof Robert Pirker, programme director for lung cancer at the Vienna General Hospital in Vienna, Austria, not involved in the study, said: «This subgroup analysis shows that the effect of necitumumab was slightly greater in patients with EGFR expressing tumours than it was in the entire SQUIRE population.
This will establish sequential crizotinib followed by a second generation ALK inhibitor as the standard treatment for patients with metastatic ALK positive lung cancer.»
«First - line immunotherapy treatment can improve survival for subset of lung cancer patients: Results of phase III global clinical trial show that 75 percent of stage IV lung cancer patients with both complex tumor mutations and PDL - 1 positive status respond to nivolumab.»
Partnering with the U.S. Food and Drug Administration allowed Doebele and colleagues to access clinical trial data describing initial tumor response, PFS and OS for 305 patients with stage IIIb or IV non-small cell lung cancer on trials of ALK inhibitors and 355 similar patients on trials of immunotherapies directed at PD - 1.
If we are able to refine a test to diagnose lung cancer by measuring breath temperature, we will improve the diagnostic process by providing patients with a stress - free and simple test that is also cheaper and less intensive for clinicians.»
This review shows uniform recognition that exercise and physical activity are safe for those with lung cancer, patients are requesting increased activity counseling, and multiple studies and reviews show potential clinical benefit in quality of life, exercise tolerance, and post-operative complications.
Testing for the EGFR mutation and ALK rearrangements and the use of targeted therapies have given lung cancer patients the chance for survival, along with improved quality of life and time with loved ones.
An analysis of lung cancer incidence and screening found a decline in the proportion of patients with lung cancer meeting high - risk screening criteria, suggesting that an increasing number of patients with lung cancer would not have been candidates for screening, according to a study in the February 24 issue of JAMA.
«Rapid advancements in genetic testing offer new treatment options for patients with advanced lung cancer.
To investigate why checkpoint inhibitors so often stop working, Velculescu; Valsamo Anagnostou, M.D., Ph.D., instructor of oncology at the Johns Hopkins University School of Medicine; Kellie N. Smith, Ph.D., a cancer immunology research associate at the Johns Hopkins University School of Medicine; and their colleagues at the Bloomberg ~ Kimmel Institute for Cancer Immunotherapy studied tumors of four patients with non-small cell lung cancer and one patient with head and neck cancer who developed resistance to two different checkpoint inhibitors: a drug called nivolumab that uses an antibody called anti-PD-1, or nivolumab used alone or in combination with a second drug called ipilimumab, which uses an antibody called anti-cancer immunology research associate at the Johns Hopkins University School of Medicine; and their colleagues at the Bloomberg ~ Kimmel Institute for Cancer Immunotherapy studied tumors of four patients with non-small cell lung cancer and one patient with head and neck cancer who developed resistance to two different checkpoint inhibitors: a drug called nivolumab that uses an antibody called anti-PD-1, or nivolumab used alone or in combination with a second drug called ipilimumab, which uses an antibody called anti-Cancer Immunotherapy studied tumors of four patients with non-small cell lung cancer and one patient with head and neck cancer who developed resistance to two different checkpoint inhibitors: a drug called nivolumab that uses an antibody called anti-PD-1, or nivolumab used alone or in combination with a second drug called ipilimumab, which uses an antibody called anti-cancer and one patient with head and neck cancer who developed resistance to two different checkpoint inhibitors: a drug called nivolumab that uses an antibody called anti-PD-1, or nivolumab used alone or in combination with a second drug called ipilimumab, which uses an antibody called anti-cancer who developed resistance to two different checkpoint inhibitors: a drug called nivolumab that uses an antibody called anti-PD-1, or nivolumab used alone or in combination with a second drug called ipilimumab, which uses an antibody called anti-CTLA4.
Although the patients» exposure to cigarettes and other hydrocarbon sources was not integrated with the results, the idea of a marker for lung cancer held up.
Clinical trials with the drugs to date have shown that nearly half of patients with lung cancers eventually develop resistance to this class of drugs for reasons that have been unclear.
«For about 80 percent of our patients with lung cancer, we don't have tests like [the one for] ALK to tell us what treatments will work best,» Shaw saFor about 80 percent of our patients with lung cancer, we don't have tests like [the one for] ALK to tell us what treatments will work best,» Shaw safor] ALK to tell us what treatments will work best,» Shaw says.
The drugs are already approved for treatment of patients with advanced breast cancer as well as ovarian, pancreatic and certain lung cancers.
Such a positive survival rate is encouraging considering that historically conventional RT resulted in poor tumor control for patients with inoperable lung cancer.
For now, the current study shows that a significant population of lung cancer patients with HER2 mutations exists.
«Lung cancer care is complicated, and all key specialists must be actively engaged early on with each patient to determine the best sequence of tests and treatment for each individual,» said Dr. Osarogiagbon.
«In this study, outcomes for HER2 - positive lung cancer patients treated with conventional therapies were similar to outcomes for HER2 - negative patients treated in the same way.
With the advancement of surgical and radiation therapy strategies for stage 1 non-small-cell lung cancer (NSCLC), more patients are being treated, resulting in higher survival rates, according to a study published online today in The Annals of Thoracic Surgery.
«This technology [stereotactic body radiation] has been used successfully in both primary and metastatic lung and liver cancers, notably for patients who could not otherwise undergo surgery, with local control rates in excess of 90 percent» says Gan.
Sarah B. Goldberg, MD, MPH, an assistant professor of medicine at the Yale School of Medicine and Yale Cancer Center, discusses osimertinib (Tagrisso) for the treatment of patients with non — small cell lung cCancer Center, discusses osimertinib (Tagrisso) for the treatment of patients with non — small cell lung cancercancer.